Latest Breaking News On - Care access research - Page 1 : comparemela.com
How do gender care bans affect health? Markey bill seeks research on anti-trans laws
gazettenet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazettenet.com Daily Mail and Mail on Sunday newspapers.
Clinical trial software company Reify hits $2 2B valuation
medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca, Care Access Research join on COVID-19 trial
outsourcing-pharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outsourcing-pharma.com Daily Mail and Mail on Sunday newspapers.
Care Access Research has teamed up with
AstraZeneca to support the Phase III clinical trial for AZD7442, AstraZeneca’s long-acting monoclonal antibody combination for the potential prevention of COVID-19.
Using Care Access’s Mobile Sites On Demand, the two will develop, deploy and manage clinical research sites across the country to assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and preemptive treatment.
“Traditional methods limit who can participate in a clinical trial and how quickly we can complete the clinical trial,” said Ahmad Namvargolian, CEO of Care Access, in a statement. “We are pleased to provide AstraZeneca the innovative capabilities they need to expedite clinical research operations for this important COVID-19 treatment candidate.”
Share
Clinical trials have become big news this year amid the search for COVID-19 vaccines and treatments. They are a critical component of helping the FDA validate that new drugs and diagnostics will be both safe and effective.
Pharmaceutical companies spend over $45B a year running clinical trials, which are, by design, very methodical and measured. Unfortunately, they are also slow, unpredictable and massively inefficient. Some estimates indicate that every day a phase 3 clinical trial slips costs the pharma company as much as $8M.
There are a lot of problems: Recruitment is often difficult, and the cost to find patients is expensive. Protocols, which can often change, may require patients to travel to specific locations or have specialists administer treatments or diagnostics.